| scholarly article | Q13442814 |
| P2093 | author name string | Ning Jin | |
| Tianyun Jiang | |||
| Barry D. Nelkin | |||
| Douglas W. Ball | |||
| David M. Rosen | |||
| P2860 | cites work | Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. | Q27851420 |
| NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. | Q27851451 | ||
| Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers | Q27851457 | ||
| Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 | ||
| Cancer statistics, 2010 | Q27860525 | ||
| Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors | Q29547463 | ||
| RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF | Q29616828 | ||
| Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer | Q29618030 | ||
| Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity | Q29618117 | ||
| Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells | Q33564297 | ||
| Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer | Q33710562 | ||
| The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors | Q33770769 | ||
| Prognostic utility of BRAF mutation in papillary thyroid cancer | Q33771120 | ||
| BAY 43-9006 inhibition of oncogenic RET mutants | Q34565246 | ||
| Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. | Q35023367 | ||
| 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors | Q35778060 | ||
| Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer | Q36822111 | ||
| Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial | Q36910409 | ||
| Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer | Q37379562 | ||
| Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. | Q37396608 | ||
| Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets | Q37397367 | ||
| Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer | Q37767709 | ||
| Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease | Q39720433 | ||
| Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells | Q42478581 | ||
| Selectively targeting mutant BRAF in thyroid cancer | Q42938752 | ||
| Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination | Q43177478 | ||
| Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. | Q43251079 | ||
| Kinase inhibitors for refractory thyroid cancers | Q45579100 | ||
| BRAF Mutations in Papillary Thyroid Carcinomas Inhibit Genes Involved in Iodine Metabolism | Q61951314 | ||
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phosphoinositide-3 kinase inhibitor | Q7187512 |
| P304 | page(s) | 6482-6489 | |
| P577 | publication date | 2011-08-10 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer | |
| Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer | |||
| P478 | volume | 17 |
| Q35578255 | A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth |
| Q42939358 | Accelerated disease progression after discontinuation of sorafenib in a patient with metastatic papillary thyroid cancer |
| Q38305056 | Advances in thyroid cancer treatment: latest evidence and clinical potential |
| Q39186912 | An update on the pathophysiology and management of polycystic liver disease |
| Q93269603 | Apoptosis Activation in Thyroid Cancer Cells by Jatrorrhizine-Platinum(II) Complex via Downregulation of PI3K/AKT/Mammalian Target of Rapamycin (mTOR) Pathway |
| Q28086785 | Autophagy in thyroid cancer: present knowledge and future perspectives |
| Q36243554 | B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer |
| Q21198860 | B-Raf and the inhibitors: from bench to bedside |
| Q53077419 | BRAFwild papillary thyroid carcinoma has two distinct mRNA expression patterns with different clinical behaviors. |
| Q39374983 | Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer. |
| Q41251561 | Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma |
| Q27852136 | Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer |
| Q37635839 | Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells |
| Q27332333 | Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 Has a Therapeutic Potential and Sensitizes Cisplatin in Nasopharyngeal Carcinoma |
| Q54117927 | Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease |
| Q38704670 | Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models |
| Q36864736 | Evolving approaches to patients with advanced differentiated thyroid cancer |
| Q92929300 | Exogenous Hydrogen Sulfide Regulates the Growth of Human Thyroid Carcinoma Cells |
| Q36799818 | FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma |
| Q38128097 | Genetics and epigenetics of sporadic thyroid cancer |
| Q28551145 | HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B |
| Q83750559 | In Search of a Real “Targeted” Therapy for Thyroid Cancer |
| Q28548302 | Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation |
| Q90194104 | Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice |
| Q34329018 | Molecular pathogenesis and mechanisms of thyroid cancer |
| Q38083427 | Multidrug Therapy for Polycystic Kidney Disease: A Review and Perspective |
| Q38239229 | PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy |
| Q38103961 | Phase I/II RAF kinase inhibitors in cancer therapy |
| Q50876534 | Possible Roles of the Xenobiotic Transporter P-glycoproteins Encoded by the MDR1 3435 C＞T Gene Polymorphism in Differentiated Thyroid Cancers |
| Q88595370 | RASSF1A Deficiency Enhances RAS-Driven Lung Tumorigenesis |
| Q34307356 | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance |
| Q37985518 | Signaling Pathways as Specific Pharmacologic Targets for Neuroendocrine Tumor Therapy: RET, PI3K, MEK, Growth Factors, and Notch |
| Q34284733 | Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines |
| Q36057504 | Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells |
| Q36208936 | TSLP Signaling Network Revealed by SILAC-Based Phosphoproteomics |
| Q91814537 | Targeting mTOR and Metabolism in Cancer: Lessons and Innovations |
| Q39130053 | Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells. |
| Q94564096 | The Altered Metabolic Molecular Signatures Contribute to the RAD001 Resistance in Gastric Neuroendocrine Tumor |
| Q38005913 | The Role of Cell Lines in the Study of Neuroendocrine Tumors |
| Q26853261 | Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma |
| Q26747168 | Treatment of advanced thyroid cancer with targeted therapies: ten years of experience |
| Q33570056 | Update: the status of clinical trials with kinase inhibitors in thyroid cancer |
| Q34450398 | Utility of a PI3K/mTOR inhibitor (NVP-BEZ235) for thyroid cancer therapy. |
| Q35025521 | Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment |
| Q37649634 | mTOR pathway in colorectal cancer: an update |
| Q37725293 | p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer |
Search more.